Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.68 is 64% above its 4-year average of -10.12, near the high end of its 4-year range (-40.44–-1.10).
6.98% below its 12-month average of -3.44.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.05.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 14 comparable quarters.
EARNINGS PER SHARE (EPS)
-3.68
EARNINGS PER SHARE (EPS) AVG TTM
-3.44
EARNINGS PER SHARE (EPS) AVG 3Y
-2.54
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.98%
CURRENT VS 3Y AVG
-45.02%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ArriVent BioPharma, Inc.
Market Cap
$1.33B
Earnings Per Share (EPS)
-3.68
TTM Avg
-3.44
3Y Avg
-2.54
5Y Avg
N/A
Market Cap
$1.34B
Earnings Per Share (EPS)
-1.04
TTM Avg
-0.49
3Y Avg
-0.48
5Y Avg
-0.41
Market Cap
$1.24B
Earnings Per Share (EPS)
-124.78
TTM Avg
-85.76
3Y Avg
-67.06
5Y Avg
-58.99
Market Cap
$1.43B
Earnings Per Share (EPS)
N/A
TTM Avg
-2.33
3Y Avg
-2.33
5Y Avg
-2.33
Market Cap
$1.21B
Earnings Per Share (EPS)
0.18
TTM Avg
0.04
3Y Avg
-0.14
5Y Avg
-0.31
Market Cap
$1.20B
Earnings Per Share (EPS)
N/A
TTM Avg
-2.04
3Y Avg
-2.04
5Y Avg
-2.04
Market Cap
$1.46B
Earnings Per Share (EPS)
5.37
TTM Avg
-2.79
3Y Avg
-4.06
5Y Avg
-3.18
Market Cap
$1.16B
Earnings Per Share (EPS)
0.04
TTM Avg
0.06
3Y Avg
0.01
5Y Avg
-0.18
Market Cap
$1.51B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $1.33B | -3.68 | -3.44 | -2.54 | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | -1.04 | -0.49 | -0.48 | -0.41 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | -124.78 | -85.76 | -67.06 | -58.99 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | -2.33 | -2.33 | -2.33 |
| Cronos Group Inc. (CRON)vs › | $1.21B | 0.18 | 0.04 | -0.14 | -0.31 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | -2.04 | -2.04 | -2.04 |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 5.37 | -2.79 | -4.06 | -3.18 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.04 | 0.06 | 0.01 | -0.18 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.51B | N/A | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.14B | -3.10 | -1.89 | -1.38 | -1.38 |
Trailing EPS (TTM)
$-3.68
Forward EPS (Est.)
$-4.23
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.32 |
| 2024-12-31 | -2.56 |
| 2023-12-31 | -2.17 |
| 2022-12-31 | -1.10 |
| 2021-12-31 | -40.44 |
